Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia? Curr Hematol Malig Rep 2013 Jun;8(2):109-15
Date
04/09/2013Pubmed ID
23563936Pubmed Central ID
PMC3661756DOI
10.1007/s11899-013-0157-2Scopus ID
2-s2.0-84878768773 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
In the past year, there has been increasing attention towards understanding the clinical relevance of minimal residual disease (MRD) assessment. The monitoring of MRD levels at various stages of therapy has considerable potential to impact the guidance of treatment for AML patients and improve outcomes. Thus, efforts have increased to address important concerns regarding MRD measurements. These concerns include: (1) what should be monitored; (2) what methodologies should be used; (3) whether such methodologies are standardized across laboratories; (4) how prognostic levels are defined; (5) when MRD should be monitored; and (6) what treatment options are available for MRD positive patients. In this review, we will discuss the methodologies available for MRD and the studies available to date aiming to address the concerns around the use of MRD measurements for AML patients.
Author List
Carlson KS, Guzman MLAuthor
Karen-Sue B. Carlson MD, PhD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultDecision Making
Flow Cytometry
Humans
Leukemia, Myeloid, Acute
Neoplasm, Residual
Polymerase Chain Reaction
